Abstract Objective To evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs). Methods Florbetapir PET was acquired in 184 subjects (45 AD patients,… Read More
SCOTTSDALE, Ariz. — Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen"… Read More
Ron Korn, M.D. of Imaging Endpoints was recently asked about his team’s work toward the integration of imagery into drug discovery and development. While full integration is a thing of the future, the use of imagery in drug discovery and development can lend significant insights into the biology and efficacy of a drug.
Abstract Progression-free survival (PFS) is increasingly used as an important and even a primary endpoint in randomized cancer clinical trials in the evaluation of patients with solid tumors for both practical and clinical considerations. Although in its simplest form, PFS… Read More
To read more click here Weiss G.J. and Korn R.L. “Interpretation of PET Scans: Do Not Take SUVs at Face Value.” J Thor Onc., 7(12): 1744-45, (2012).
BACKGROUND: Inhibition of the hedgehog signaling pathway (HHSP) for the treatment of locally advanced basal cell carcinoma (BCC) and metastatic BCC (mBCC) has produced promising results. Typically, mBCC is not taken into consideration during the workup of a patient with… Read More
Abstract The use of 18-fluorodeoxyglucose (FDG) positron emission tomography with computed tomography (PET/CT) in subjects with advanced basal cell carcinoma (BCC) has not been fully explored due to the rarity of disease presentation. This study evaluated PET/CTs from subjects with… Read More
The ACR’s mission statement identifies five pillars of excellence. One of its pillars is research. ACR is recognized by many as supporting one of the premier research endeavors sponsored by a professional medical society of which the ACR Clinical Research… Read More
Purpose The trial objectives were to identify the maximum-tolerated dose (MTD) of first-line gemcitabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma and to provide efficacy and safety data. Additional objectives were to evaluate positron emission tomography (PET) scan response, secreted protein… Read More
Abstract Dynamic Contrast-Enhanced MRI (DCE-MRI) is increasingly in use as an investigational biomarker of response in cancer clinical studies. Proper registration of images acquired at different time-points is essential for deriving diagnostic information from quantitative pharmacokinetic analysis of these data.… Read More